In vivo MRS of locally advanced breast cancer: Characteristics related to negative or positive choline detection and early monitoring of treatment response

Magnetic Resonance Materials in Physics, Biology and Medicine

Volumn 24, Issue 6, 2011, Pages 347-357

  Bathen, Tone F ^a   Heldahl, Mariann G ^a   Sitter, Beathe ^a   Vettukattil, Riyas ^a   Bofin, Anna ^b   Lundgren, Steinar ^b,c   Gribbestad, Ingrid S ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Choline; Locally advanced breast cancer (LABC); Magnetic resonance spectroscopy; Neoadjuvant chemotherapy (NAC); Treatment response

Indexed keywords

CHOLINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST TUMOR; CHEMISTRY; FEMALE; HUMAN; METABOLISM; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PAGET NIPPLE DISEASE; PROGNOSIS; SIGNAL NOISE RATIO; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHOLINE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; SIGNAL-TO-NOISE RATIO; TREATMENT OUTCOME;

EID: 84874686616     PISSN: 09685243     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10334-011-0280-9     Document Type: Article

References (43)

1. Kvistad KA, Bakken IJ, Gribbestad IS, Ehrnholm B, Lundgren S, Fjosne HE, Haraldseth O (1999) Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging 10:159-164
2. Kim JK, Park SH, Lee HM, Lee YH, Sung NK, Chung DS, Kim OD (2003) In vivo 1H-MRS evaluation of malignant and benign breast diseases. Breast 12:179-182
3. Yeung DK, Cheung HS, Tse GM (2001) Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy - initial results. Radiology 220:40-46
4. Bartella L, Thakur SB, Morris EA, Dershaw DD, Huang W, Chough E, Cruz MC, Liberman L (2007) Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy. Radiology 245:80-87
5. Huang W, Fisher PR, Dulaimy K, Tudorica LA, O'Hea B, Button TM (2004) Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology 232:585-591
6. Roebuck JR, CecilKM, Schnall MD, Lenkinski RE (1998) Human breast lesions: characterization with proton MR spectroscopy. Radiology 209:269-275
7. Bartella L, Morris EA, Dershaw DD, Liberman L, Thakur SB, Moskowitz C, Guido J, HuangW (2006) Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study.Radiology 239:686-692
8. Meisamy S, Bolan PJ, Baker EH et al (2005) Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T. Radiology 236:465-475
9. Bolan PJ, Meisamy S, Baker EH, Lin J, Emory T, Nelson M, Everson LI, Yee D, Garwood M (2003) In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 50:1134-1143
10. Baek HM, Chen JH, Nalcioglu O, SuMY (2008) Proton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 19:1022-1024
11. Baek HM,Chen JH, NieK,YuHJ, Bahri S,Mehta RS,NalciogluO, Su MY (2009) Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology 251:653-662
12. Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK (2001) Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 84:1016-1022
13. Meisamy S, Bolan PJ, Baker EH et al (2004) Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy - apilot study at 4 T.Radiology 233:424-431
14. Danishad KK, Sharma U, Sah RG, Seenu V, Parshad R, Jagannathan NR (2010) Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI). NMR Biomed 23:233-241
15. Haddadin IS, McIntosh A, Meisamy S, Corum C, Styczynski Snyder AL, Powell NJ, Nelson MT, Yee D, Garwood M, Bolan PJ (2009) Metabolite quantification and high-field MRS in breast cancer. NMR Biomed 22:65-76
16. Glunde K, Jie C, Bhujwalla ZM (2004) Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 64:4270-4276
17. EliyahuG, Kreizman T,DeganiH (2007) Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer 120:1721-1730
18. Bathen TF, Jensen LR, Sitter B, Fjosne HE, Halgunset J, Axelson DE, Gribbestad IS, Lundgren S (2007) MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat 104:181-189
19. Giskeodegard GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjosne HE, Dahl S, Gribbestad IS, Bathen TF (2010) Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res 9:972-979
20. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS (2006) Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 19:30-40
21. Bathen TF, Sitter B, Sjobakk TE, Tessem MB, Gribbestad IS (2010) Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res 70:6692-6696
22. Smith SM, Jenkinson M, Woolrich MW et al (2004) Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage 23:S208-S219
23. Lehman CD, Peacock S, DeMartini WB, Chen X (2006) A new automated software system to evaluate breast MR examinations: improved specificity without decreased sensitivity. Am J Roentgenol 187:51-56
24. Heldahl MG, Bathen TF, Rydland J, Kvistad KA, Lundgren S, Gribbestad IS, Goa PE (2010) Prognostic value of pretreatment dynamic contrast-enhanced MR imaging in breast cancer patients receiving neoadjuvant chemotherapy: overall survival predicted from combined time course and volume analysis. Acta Radiol 51:604-612
25. Naressi A, Couturier C, Castang I, Beer Rde, Graveron-Demilly D (2001) Java-based graphical user interface forMRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med 31:269-286
26. Sitter B, Bathen TF, Singstad TE, Fjosne HE, Lundgren S, Halgunset J, Gribbestad IS (2010) Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed 23:424-431
27. Baik HM, SuMY, Yu H, Mehta R, Nalcioglu O (2006) Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T. Magn Reson Mater Phys 19:96-104
28. Lenkinski RE, Wang X, Elian M, Goldberg SN (2009) Interaction of gadolinium-based MR contrast agents with choline: implications for MR spectroscopy (MRS) of the breast. Magn Reson Med 61:1286-1292
29. Sharma U, Kumar M, Sah RG, Jagannathan NR (2009) Study of normal breast tissue by in vivo volume localized proton MR spectroscopy: variation ofwater-fat ratio in relation to the heterogeneity of the breast and themenstrual cycle. Magn Reson Imaging 27:785-791
30. Choyke PL, Dwyer AJ,KnoppMV (2003) Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 17:509-520
31. Knopp MV,Weiss E, Sinn HP et al (1999) Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10:260-266
32. TozakiM, Hoshi K (2010) 1H MR spectroscopy of invasive ductal carcinoma: correlations with FDG PET and histologic prognostic factors. Am J Roentgenol 194:1384-1390
33. Tozaki M, Sakamoto M, Oyama Y, Maruyama K, Fukuma E (2010) Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method. J Magn Reson Imaging 31:895-902
34. Morse DL, Raghunand N, Sadarangani P, Murthi S, Job C, Day S, Howison C, Gillies RJ (2007) Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by highresolution (31)P NMR spectroscopy of cell extracts. Magn Reson Med 58:270-280
35. Sterin M, Cohen JS, Mardor Y, Berman E, Ringel I (2001) Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study. Cancer Res 61:7536-7543
36. Kumar M, Jagannathan NR, Seenu V, Dwivedi SN, Julka PK, Rath GK (2006) Monitoring the therapeutic response of locally advanced breast cancer patients: sequential in vivo proton MR spectroscopy study. J Magn Reson Imaging 24:325-332
37. Jagannathan NR, Singh M, Govindaraju V, Raghunathan P, Coshic O, Julka PK, Rath GK (1998) Volume localized in vivo proton M spectroscopy of breast carcinoma: variation of water-fat ratio in patients receiving chemotherapy. NMR Biomed 11:414-422
38. Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A, Pickles MD, Tozer DJ, Turnbull LW (2006) Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 94:427-435
39. Chollet P, Amat S, Cure H, Latour Mde, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J, Penault-Llorca F (2002) Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 86:1041-1046
40. Guarneri V, Broglio K, Kau SW et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037-1044
41. Chen AM, Meric-Bernstam F, Hunt KK et al (2004) Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 22:2303-2312
42. Baek HM, Chen JH, Yu HJ, Mehta R, Nalcioglu O, Su MY (2008) Detection of choline signal in human breast lesions with chemical-shift imaging. J Magn Reson Imaging 27:1114-1121
43. Bakken IJ, Gribbestad IS, Singstad TE, Kvistad KA (2001) External standard method for the in vivo quantification of cholinecontaining compounds in breast tumors by protonMRspectroscopy at 1.5 Tesla. Magn Reson Med 46:189-192